

# Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HBE765B76E7EN.html>

Date: May 2020

Pages: 61

Price: US\$ 2,000.00 (Single User License)

ID: HBE765B76E7EN

## Abstracts

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis – Pipeline Review, H1 2020, provides an overview of the Herpes Labialis (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Herpes Labialis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase

III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 5 and 1 respectively.

Herpes Labialis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Herpes Labialis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Herpes Labialis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Herpes Labialis (Oral Herpes) - Overview

Herpes Labialis (Oral Herpes) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Herpes Labialis (Oral Herpes) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development

AiCuris GmbH & Co KG

Astellas Pharma Inc

Brandenburg Antiinfektiva GmbH

Dobecure SL

NanoViricides Inc

Provention Bio Inc

Shulov Innovative Science Ltd

Squarex LLC

Vironova Medical AB

Herpes Labialis (Oral Herpes) - Drug Profiles

amenamevir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ethamsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVHHV-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pritelivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRV-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Herpes Labialis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

squaric acid dibutyl ester - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEP-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Herpes Labialis (Oral Herpes) - Dormant Projects

Herpes Labialis (Oral Herpes) - Discontinued Products

Herpes Labialis (Oral Herpes) - Product Development Milestones

Featured News & Press Releases

Aug 05, 2019: Squarex announces positive results from completed phase 2 study of SQX770 in the prevention of recurrent herpes labialis

Jul 01, 2019: Squarex appoints biopharmaceutical industry veteran Jack V. Talley as chief executive officer

Feb 14, 2019: Squarex Announces Publication of Clinical Results for SQX770 for the

## Prevention of Herpes Outbreaks in Immunity, Inflammation and Disease

Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

May 24, 2017: Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by Astellas Pharma Inc, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by Brandenburg Antiinfektiva GmbH, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by Dobecure SL, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by Provention Bio Inc, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by Squarex LLC, H1 2020  
Herpes Labialis (Oral Herpes) - Pipeline by Vironova Medical AB, H1 2020  
Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2020  
Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AiCuris GmbH & Co KG

Astellas Pharma Inc

Brandenburg Antiinfektiva GmbH

Dobecure SL

NanoViricides Inc

Provention Bio Inc

Shulov Innovative Science Ltd

Squarex LLC

Vironova Medical AB



## I would like to order

Product name: Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HBE765B76E7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HBE765B76E7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970